A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of therapeutic
options for many cancers. These treatments have demonstrated improved efficacy and often …

Background Some concomitant medications including antibiotics (ATB) have been
reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in …

Background A proinflammatory diathesis, as measured by the neutrophil to lymphocyte ratio
(NLR), heralds an adverse disease course for non–small cell lung cancer (NSCLC) …

Peripheral blood inflammatory indices, like the neutrophil-to-lymphocyte ratio (NLR), may
reflect the host's pro-inflammatory status and systemic immune response to cancer-related …

Neoadjuvant immunotherapy has emerged as a promising approach in the treatment of
various malignancies, with preclinical studies showing improved immune responses in the …

Background Immunotherapy represents the standard of care in the first-line treatment of
advanced non-small-cell lung cancer (NSCLC), either as monotherapy in high programmed …

Background Liver metastasis is the most common type of lung cancer metastasis, and is a
significant prognostic factor in lung cancer. However, the effect of liver metastases on the …

Background Efficacy outcomes and prognostic factors of real-world patients with advanced
non-small cell lung cancer (aNSCLC) treated with first-line chemoimmunotherapy are still …

Purpose of review To describe the biological rationale of peripheral blood cells (PBC)–
derived inflammatory indexes and assess the related prognostic scores for patients with …